mTOR expression is high in patients with hepatocellular carcinoma (HCC) that have vessels that encapsulate tumor clusters, suggesting that the mTOR inhibitor, everolimus, could be particularly affective in patients with HCC being treated using living donor liver transplantation. This evidence concerns the gene MTOR and hepatocellular carcinoma.